Clinical Trials for Pancreas Cancer

A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients with Advanced Cancer with and Without Pembrolizumab

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, locally advanced or metastatic solid tumors and ECOG 0–1, generally without remaining standard options, receive oral LNS8801 alone or with pembrolizumab; disease-specific cohorts include melanoma, pancreatic, gastric, NSCLC, and colorectal cancers. LNS8801 is an investigational selective agonist of the G protein-coupled estrogen receptor (GPER), and pembrolizumab is an anti-PD-1 antibody.

ClinicalTrials.gov ID: NCT04130516

First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced EGFR-driven solid tumors, including selected head and neck, anal, cutaneous, lung, and colorectal cancers, receive intravenous BCA101 alone or with pembrolizumab, depending on the cohort. BCA101 is a bifunctional anti-EGFR antibody fused to a TGF-β receptor domain that inhibits EGFR signaling and traps TGF-β.

ClinicalTrials.gov ID: NCT04429542

A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy in Patients With Advanced Solid Tumours

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable metastatic or unresectable gastrointestinal cancers receive intravenous BOLD-100 plus FOLFOX (fluorouracil, leucovorin and oxaliplatin); the open second-line colorectal cohort requires BRAF wild-type, microsatellite-stable disease and no prior oxaliplatin. BOLD-100 is an investigational ruthenium-based agent that suppresses stress-induced GRP78 expression in laboratory studies, though its mechanism in patients remains uncertain.

ClinicalTrials.gov ID: NCT04421820

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors, including ATM-altered cancers and platinum-resistant ovarian cancer, receive the oral ATR kinase inhibitor ART0380 (alnodesertib) alone or with gemcitabine or irinotecan. The ovarian cancer cohort compares ART0380 plus gemcitabine with gemcitabine alone.

ClinicalTrials.gov ID: NCT04657068

Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic GI adenocarcinomas (colorectal, pancreaticobiliary, or upper GI) progressing after standard therapy receive sacituzumab govitecan (Trop-2–targeted ADC delivering SN-38/topoisomerase I inhibitor) plus capecitabine in 21-day cycles; prior topo I inhibitor exposure is excluded, treated/stable brain mets allowed. Dose-escalation assesses safety/tolerability and seeks an RP2D, with exploratory correlation to tumor Trop-2 expression.

ClinicalTrials.gov ID: NCT06065371

ParpVax2: A Phase II Study Of Maintenance Niraparib Plus Ipilimumab In Patients With Metastatic Pancreatic Cancer Whose Disease Has Not Progressed On Platinum-Based Therapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic pancreatic adenocarcinoma with at least stable disease after 8–12 cycles of platinum-based induction (FOLFIRINOX or NALIRIFOX; ECOG 0–1) are randomized to maintenance niraparib (PARP-1/2 inhibitor) plus ipilimumab (CTLA-4 inhibitor) versus continued chemotherapy (FOLFIRI). Key exclusions include prior PARP/CTLA-4 therapy, known pathogenic BRCA1/2/PALB2/RAD51C/D alterations, and dMMR/MSI-H disease.

ClinicalTrials.gov ID: NCT06747845

Treatment of Patients With Metastatic Pancreatic Cancer With Gemcitabine and Nab-Paclitaxel and Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic pancreatic adenocarcinoma (ECOG 0–1) receive standard gemcitabine plus nab-paclitaxel combined with the TheraBionic P1 device delivering amplitude-modulated radiofrequency electromagnetic fields, a noninvasive biophysical modality hypothesized to disrupt tumor signaling and proliferation. Excludes recent gemcitabine/nab-paclitaxel in the adjuvant/neoadjuvant setting, brain metastases, and patients on L- or T-type calcium channel blockers unless discontinued.

ClinicalTrials.gov ID: NCT06576115

A Phase 2 Multi-center, Open-label, Single Arm Study of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with well-differentiated, unresectable or metastatic GI, lung, or pancreatic NETs (functional or non-functional) with measurable disease, ECOG 0–1, and ≤2 prior systemic lines (excluding SSAs), but no prior mTOR inhibitors, receive nab-sirolimus monotherapy. Nab-sirolimus is an albumin-bound sirolimus (mTORC1 inhibitor) formulation designed to enhance tumor delivery; functional NETs must be on a stable SSA dose with documented progression.

ClinicalTrials.gov ID: NCT05997056

A Phase 1/2, Open-Label, Dose Escalation and Expansion Study With PT886 (Spevatamig) Followed by a Multi-cohorT Study in Patients With Advanced GastrIc, Gastroesophageal JuNction, Pancreatic Ductal or Biliary Tract AdEnocarcinomas of PT886, in Combination With ChemotherApy, and/or an Immune ChecKpoint Inhibitor. The TWINPEAK Study

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, pancreatic ductal adenocarcinoma, or biliary tract cancer receive spevatamig, a CLDN18.2/CD47-targeting bispecific antibody, alone or with chemotherapy and/or pembrolizumab. Combination cohorts require CLDN18.2-positive tumor tissue; eligibility and treatment regimens vary by cohort.

ClinicalTrials.gov ID: NCT05482893

Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated advanced or refractory solid tumors or eligible B- or T-cell lymphomas receive oral ZEN003694, a BET inhibitor, plus entinostat, a class I HDAC inhibitor, in dose escalation. The expansion cohort focuses on locally advanced unresectable or metastatic pancreatic cancer refractory to standard therapy.

ClinicalTrials.gov ID: NCT05053971